StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) stock

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)

Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –

Harmony Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Harmony Biosciences's price to sales ratio was 2.1× on Nov 11, 2026, against 2.5× a year earlier. Over the last 5 years it ranged from 1.9× to 9.4×, with a median of 3.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.1×−0.5
2025Dec 31, 20252.6×−0.3
2024Dec 31, 20242.9×−0.6
2023Dec 29, 20233.5×−4.7
2022Dec 30, 20228.2×−1.1
2021Dec 31, 20219.2×–

More Harmony Biosciences figures

See a number that looks wrong?